Myeloproliferative Neoplasms | Specialty

Rapid Readouts: Phase 2 Study of Navitoclax in High-Risk Myelofibrosis

January 15th 2021

Maximizing the Management of MPNs

January 13th 2021

January 13, 2021 - Defining treatment goals for patients with myeloproliferative neoplasms is critical in order to optimize therapy, even if the dominant concern is disease progression.

Momelotinib Trial Seeks to Address Myelofibrosis Symptoms

January 6th 2021

January 6, 2021 - The MOMENTUM trial will randomize patients to receive momelotinib or danazol to determine which regimen shows more efficacy against the MF hallmarks of anemia, constitutional symptoms, and splenomegaly.

Pacritinib at Recommended Phase 3 Dose Showcases Clinical Activity in Myelofibrosis With Severe Thrombocytopenia

December 24th 2020

December 23, 2020 - Pacritinib, when delivered at a twice-daily dose of 200 mg, was found to demonstrate clinical activity with an acceptable toxicity profile in patients with myelofibrosis and severe thrombocytopenia.

Ropeginterferon-Treated Patients With Polycythemia Vera Significantly More Likely to Be Phlebotomy Free at 5 Years

December 22nd 2020

December 22, 2020 - Patients with polycythemia vera who received ropeginterferon alfa-2b had a higher likelihood of being phlebotomy free in the fourth or fifth year of treatment vs those who received best available therapy.

Idasanutlin Induces Responses in Polycythemia Vera, but GI AEs Lead to Frequent Dose Interruptions

December 22nd 2020

December 22, 2020 - Idasanutlin, an investigational MDM2 antagonist that leads to increased p53 activity, led to hematologic responses in about two-thirds of patients with hydroxyurea-resistant polycythemia vera, but was associated with frequent discontinuation.

Interferon-Alpha Reduces Myelofibrosis Risk, Mortality Rate in Low- and High-Risk Polycythemia Vera

December 21st 2020

December 21, 2020 - Interferon-alpha can delay and possibly prevent post-PV myelofibrosis and improve survival in patients with polycythemia vera.

FDA Approval Sought for Avapritinib in Advanced Systemic Mastocytosis

December 18th 2020

December 18, 2020 - A supplemental new drug application has been submitted to the FDA for avapritinib for use as a treatment in adult patients with advanced systemic mastocytosis.

Dr. Verstovsek on the Role of Ruxolitinib in Myelofibrosis

December 16th 2020

Srdan Verstovsek, MD, PhD, discusses the role of ruxolitinib in myelofibrosis.

Dr. Spivak on Diagnosing Essential Thrombocythemia

December 9th 2020

Jerry L​e Pow Spivak, MD, discusses diagnosing essential thrombocythemia.

Dr. Rampal on the Evolution of Prognostic Models in Essential Thrombocythemia

December 8th 2020

Raajit K. Rampal, MD, PhD, discusses the evolution of prognostic models in essential thrombocythemia.

Driver Mutations Detectable in Utero, Used to Calculate MPN Diagnosis

December 8th 2020

JAK2 and DNMT3A driver mutations can be acquired as early as in utero in patients with myeloproliferative neoplasms, demonstrating variable rates of clonal expansion and growth that influence the time to diagnosis.

Dr. Mesa on the Anticipated Utility of Momelotinib in Myelofibrosis

December 7th 2020

Ruben A. Mesa, MD, discusses the anticipated utility of momelotinib in myelofibrosis.

Dr. Verstovsek on the Results of the PV-AIM trial in Polycythemia Vera

December 5th 2020

Srdan Verstovsek, MD, PhD, discusses findings from the PV-AIM trial in polycythemia vera.

Momelotinib Sustains Long-Term Survival in Patients With Myelofibrosis

December 5th 2020

December 5, 2020 - Momelotinib improved overall survival and sustained efficacy outcomes in patients with intermediate- or high-risk myelofibrosis.

High-Dose Imetelstat Improves Overall Survival and Offers Clinical Benefits in High-Risk Myelofibrosis

December 5th 2020

December 5, 2020 - Patients with myelofibrosis who are relapsed after or refractory to therapy with Janus kinase inhibitors saw better overall survival, spleen response, and symptom response with higher doses of the telomerase inhibitor imetelstat.

Navitoclax/Ruxolitinib Combo Improves Spleen Volume, Symptoms in Relapsed/Refractory Myelofibrosis

December 5th 2020

December 5, 2020 - The addition of navitoclax to ruxolitinib resulted in a clinically meaningful improvement in spleen volume and total symptom score in patients with myelofibrosis who no longer benefited from prior ruxolitinib therapy.

Dr. El Chaer on the Role of Next-Generation Sequencing in MPNs

December 4th 2020

Firas El Chaer, MD, discusses the role of next-generation sequencing (NGS) in myeloproliferative neoplasms.

Dr. Bose on Risk Factors of Essential Thrombocythemia

December 3rd 2020

Prithviraj Bose, MD, discusses risk factors associated with essential thrombocythemia.

Dr. Mascarenhas on the Role of Genetic Testing in MPNs

December 2nd 2020

John O. Mascarenhas, MD, discusses the role of genetic testing in myeloproliferative neoplasms.